Compare MAN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | MESO |
|---|---|---|
| Founded | 1948 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 1994 | 2005 |
| Metric | MAN | MESO |
|---|---|---|
| Price | $61.90 | $17.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $35.67 | N/A |
| AVG Volume (30 Days) | ★ 771.1K | 179.9K |
| Earning Date | 04-16-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $17,957,100,000.00 | N/A |
| Revenue This Year | $5.12 | $629.74 |
| Revenue Next Year | $3.42 | $30.65 |
| P/E Ratio | $51.24 | ★ N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $13.05 |
| 52 Week High | $63.88 | $21.50 |
| Indicator | MAN | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 63.19 | 53.65 |
| Support Level | $25.93 | $16.56 |
| Resistance Level | N/A | $17.33 |
| Average True Range (ATR) | 2.12 | 0.47 |
| MACD | -0.57 | -0.04 |
| Stochastic Oscillator | 60.86 | 32.80 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.